N4 Pharma Chengzhong Yu Awarded Grant to Work on Patented Nuvec® Nanoparticle
N4 Pharma Plc (N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce it will be supporting the University of Queensland as part of a recent grant award by the Australian Research Council.
The University of Queensland has announced that Professor Chengzhong Yu, Senior Group Leader, Australian Institute for Bioengineering and Nanotechnology (AIBN) has been awarded a $402,115 grant to develop an improved nanoparticle delivery system that enhances the performance of messenger ribonucleic acid (mRNA) therapies. The new nanoparticle will be based on the Company’s patented nuvec® nanoparticle that it has licensed exclusively from the University of Queensland.
N4 Pharma will work with Professor Yu to tackle the current challenges in manufacturing mRNA therapeutics, by building new knowledge in custom-design of functional nanomaterials for mRNA delivery. mRNA is a highly lucrative field of therapeutic science and is emerging as a major drug platform.
“We will be working on new technology that brings clear commercial benefits, not just for our industry partner, but the wider mRNA industry and biopharma sector,” Professor Yu said.
Nigel Theobald, Chief Executive Officer of the Company, commented:
“We are pleased to continue our close collaboration with Professor Yu and work on new ways to build on the performance of our Nuvec® nanoparticle together.”
Read the original article on DirectorsTalk Interviews.